Estrogen receptor beta in breast cancer-Diagnostic and therapeutic implications

Steroids

Volumn 74, Issue 8, 2009, Pages 635-641

  Hartman, Johan ^a,b   Ström, Anders ^a,b   Gustafsson, Jan Åke ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Houston   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell cycle; Phytoestrogens; Proliferation; Tumor growth

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GONADORELIN DERIVATIVE; ISOFLAVONE; LETROZOLE; MYC PROTEIN; PHYTOESTROGEN; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CELL PROLIFERATION; DRUG ELIMINATION; DRUG METABOLISM; ENDOTHELIUM CELL; ESTROGEN BINDING; FIBROBLAST; HUMAN; LYMPHOCYTIC INFILTRATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN RECEPTOR BETA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHYTOESTROGENS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349223542     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2009.02.005     Document Type: Review

References (109)

1. Huang Z., Hankinson S.E., Colditz G.A., Stampfer M.J., Hunter D.J., Manson J.E., et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 278 (1997) 1407-1411
2. Kroenke C.H., Fung T.T., Hu F.B., and Holmes M.D. Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23 (2005) 9295-9303
3. Kelsey J.L. A review of the epidemiology of human breast cancer. Epidemiol Rev 1 (1979) 74-109
4. Jensen E.V., and DeSombre E.R. Estrogen-receptor interaction. Science 182 (1973) 126-134
5. Couse J.F., Lindzey J., Grandien K., Gustafsson J.A., and Korach K.S. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138 (1997) 4613-4621
6. Gonzalez M., Cabrera-Socorro A., Perez-Garcia C.G., Fraser J.D., Lopez F.J., Alonso R., et al. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. J Comp Neurol 503 (2007) 790-802
7. Iwai T., Nanbu Y., Iwai M., Taii S., Fujii S., and Mori T. Immunohistochemical localization of oestrogen receptors and progesterone receptors in the human ovary throughout the menstrual cycle. Virchows Arch A Pathol Anat Histopathol 417 (1990) 369-375
8. Assikis V.J., and Jordan V.C. Risks and benefits of tamoxifen therapy. Oncology (Williston Park) 11 (1997) 21-23
9. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93 (1996) 5925-5930
10. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G., et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275 (2000) 5379-5387
11. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
12. Makela S., Strauss L., Kuiper G., Valve E., Salmi S., Santti R., et al. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol 164 (2000) 109-116
13. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 (1997) 863-870
14. Menasce L.P., White G.R., Harrison C.J., and Boyle J.M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25,1 by FISH and a simple post-FISH banding technique. Genomics 17 (1993) 263-265
15. Enmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82 (1997) 4258-4265
16. Matthews J., and Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3 (2003) 281-292
17. Zhao C., Dahlman-Wright K., and Gustafsson J.A. Estrogen receptor beta: an overview and update. Nucl Recept Signal 6 (2008) e003
18. Delaunay F., Pettersson K., Tujague M., and Gustafsson J.A. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58 (2000) 584-590
19. Liu Y., Gao H., Marstrand T.T., Strom A., Valen E., Sandelin A., et al. The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc Natl Acad Sci USA 105 (2008) 2604-2609
20. Moore J.T., McKee D.D., Slentz-Kesler K., Moore L.B., Jones S.A., Horne E.L., et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247 (1998) 75-78
21. Fuqua S.A., Schiff R., Parra I., Friedrichs W.E., Su J.L., McKee D.D., et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59 (1999) 5425-5428
22. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26 (1998) 3505-3512
23. Zhao C., Matthews J., Tujague M., Wan J., Strom A., Toresson G., et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67 (2007) 3955-3962
24. Hall J.M., Couse J.F., and Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276 (2001) 36869-36872
25. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74 (2000) 311-317
26. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 (2000) 227-251
27. O'Malley B.W. Coregulators: from whence came these "master genes". Mol Endocrinol 21 (2007) 1009-1013
28. Cheng G., Weihua Z., Warner M., and Gustafsson J.A. Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci USA 101 (2004) 3739-3746
29. Saji S., Jensen E.V., Nilsson S., Rylander T., Warner M., and Gustafsson J.A. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci USA 97 (2000) 337-342
30. Jensen E.V., Cheng G., Palmieri C., Saji S., Makela S., Van Noorden S., et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98 (2001) 15197-15202
31. Park B.W., Kim K.S., Heo M.K., Ko S.S., Hong S.W., Yang W.I., et al. Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?. Breast Cancer Res Treat 80 (2003) 79-85
32. Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.T., Coombes R.C., et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22 (2003) 7600-7606
33. Lippman M., Bolan G., and Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36 (1976) 4595-4601
34. Strom A., Hartman J., Foster J.S., Kietz S., Wimalasena J., and Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101 (2004) 1566-1571
35. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
36. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 100 (2000) 71-78
37. Sotoca A.M., van den Berg H., Vervoort J., van der Saag P., Strom A., Gustafsson J.A., et al. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 105 (2008) 303-311
38. Helguero L.A., Faulds M.H., Gustafsson J.A., and Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24 (2005) 6605-6616
39. Zhang L., and Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 25 (2006) 2615-2627
40. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64 (2004) 423-428
41. Garmy-Susini B., and Varner J.A. Circulating endothelial progenitor cells. Br J Cancer 93 (2005) 855-858
42. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
43. Haran E.F., Maretzek A.F., Goldberg I., Horowitz A., and Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54 (1994) 5511-5514
44. Makris A., Powles T.J., Kakolyris S., Dowsett M., Ashley S.E., and Harris A.L. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85 (1999) 1996-2000
45. Johns A., Freay A.D., Fraser W., Korach K.S., and Rubanyi G.M. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137 (1996) 4511-4513
46. Zaitseva M., Yue D.S., Katzenellenbogen J.A., Rogers P.A., and Gargett C.E. Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. J Soc Gynecol Investig 11 (2004) 529-535
47. Morales D.E., McGowan K.A., Grant D.S., Maheshwari S., Bhartiya D., Cid M.C., et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91 (1995) 755-763
48. Suzuma I., Mandai M., Takagi H., Suzuma K., Otani A., Oh H., et al. 17 Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 40 (1999) 2122-2129
49. Ginsburg E., and Vonderhaar B.K. Stimulation of growth of human breast cancer cells (T47D) by platelet derived growth factor. Cancer Lett 58 (1991) 137-144
50. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116 (2006) 1561-1570
51. Lin E.Y., and Pollard J.W. Macrophages: modulators of breast cancer progression. Novartis Found Symp 256 (2004) 259-269 [158-68; discussion 168-72]
52. Shim G.J., Gherman D., Kim H.J., Omoto Y., Iwase H., Bouton D., et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 208 (2006) 408-414
53. Sherman T.S., Chambliss K.L., Gibson L.L., Pace M.C., Mendelsohn M.E., Pfister S.L., et al. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 26 (2002) 610-616
54. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998) 4252-4263
55. Kolonel L.N. Variability in diet and its relation to risk in ethnic and migrant groups. Basic Life Sci 43 (1988) 129-135
56. Parkin D.M. Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol 25 (1989) 1917-1925
57. Setchell K.D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68 (1998) 1333S-1346S
58. Sirtori C.R., Arnoldi A., and Johnson S.K. Phytoestrogens: end of a tale?. Ann Med 37 (2005) 423-438
59. Rowland I.R., Wiseman H., Sanders T.A., Adlercreutz H., and Bowey E.A. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equal production by the gut microflora. Nutr Cancer 36 (2000) 27-32
60. Rowland I., Wiseman H., Sanders T., Adlercreutz H., and Bowey E. Metabolism of oestrogens and phytoestrogens: role of the gut microflora. Biochem Soc Trans 27 (1999) 304-308
61. Dixon-Shanies D., and Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 6 (1999) 1383-1387
62. Matsumura A., Ghosh A., Pope G.S., and Darbre P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 94 (2005) 431-443
63. Hsieh C.Y., Santell R.C., Haslam S.Z., and Helferich W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58 (1998) 3833-3838
64. Allred C.D., Allred K.F., Ju Y.H., Virant S.M., and Helferich W.G. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 61 (2001) 5045-5050
65. Lamartiniere C.A., Zhang J.X., and Cotroneo M.S. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 68 (1998) 1400S-1405S
66. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 (1987) 5592-5595
67. Dai Q., Shu X.O., Jin F., Potter J.D., Kushi L.H., Teas J., et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 85 (2001) 372-378
68. Shu X.O., Jin F., Dai Q., Wen W., Potter J.D., Kushi L.H., et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 10 (2001) 483-488
69. Ingram D., Sanders K., Kolybaba M., and Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 350 (1997) 990-994
70. Trock B.J., Hilakivi-Clarke L., and Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98 (2006) 459-471
71. Linseisen J., Piller R., Hermann S., and Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 110 (2004) 284-290
72. Keinan-Boker L., van Der Schouw Y.T., Grobbee D.E., and Peeters P.H. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 79 (2004) 282-288
73. Lamartiniere C.A. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 7 (2002) 67-76
74. Thanos J., Cotterchio M., Boucher B.A., Kreiger N., and Thompson L.U. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 17 (2006) 1253-1261
75. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61 (2001) 2537-2541
76. Bardin A., Boulle N., Lazennec G., Vignon F., and Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11 (2004) 537-551
77. Skliris G.P., Munot K., Bell S.M., Carder P.J., Lane S., Horgan K., et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201 (2003) 213-220
78. Shaaban A.M., Jarvis C., Moore F., West C., Dodson A., and Foster C.S. Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29 (2005) 1593-1599
79. Dotzlaw H., Leygue E., Watson P.H., and Murphy L.C. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 59 (1999) 529-532
80. Speirs V., Malone C., Walton D.S., Kerin M.J., and Atkin S.L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59 (1999) 5421-5424
81. Leygue E., Dotzlaw H., Watson P.H., and Murphy L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58 (1998) 3197-3201
82. Skliris G.P., Carder P.J., Lansdown M.R., and Speirs V. Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?. Br J Cancer 84 (2001) 1095-1098
83. Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes A., et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32 (2001) 113-118
84. Hopp T.A., Weiss H.L., Parra I.S., Cui Y., Osborne C.K., and Fuqua S.A. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10 (2004) 7490-7499
85. Omoto Y., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163 (2001) 207-212
86. Jarvinen T.A., Pelto-Huikko M., Holli K., and Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156 (2000) 29-35
87. Esslimani-Sahla M., Kramar A., Simony-Lafontaine J., Warner M., Gustafsson J.A., and Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11 (2005) 3170-3174
88. Shaaban A.M., Green A.R., Karthik S., Alizadeh Y., Hughes T.A., Harkins L., et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14 (2008) 5228-5235
89. Skliris G.P., Leygue E., Curtis-Snell L., Watson P.H., and Murphy L.C. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95 (2006) 616-626
90. O'Neill P.A., Davies M.P., Shaaban A.M., Innes H., Torevell A., Sibson D.R., et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91 (2004) 1694-1702
91. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 (1995) 1491-1494
92. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2 (2002) 101-112
93. Tremblay A., Tremblay G.B., Labrie F., and Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3 (1999) 513-519
94. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
95. Umekita Y., Souda M., Ohi Y., Sagara Y., Rai Y., Takahama T., et al. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathol Int 56 (2006) 423-427
96. Tamoxifen, for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 (1998) 1451-1467
97. Jordan V.C. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72 (2007) 829-842
98. Love R.R., Newcomb P.A., Wiebe D.A., Surawicz T.S., Jordan V.C., Carbone P.P., et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82 (1990) 1327-1332
99. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., and Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86 (1994) 1534-1539
100. Patel R.R., Sharma C.G., and Jordan V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14 (2007) 113-122
101. Berry M., Metzger D., and Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9 (1990) 2811-2818
102. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
103. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10 (2004) 5769-5776
104. Borgquist S., Holm C., Stendahl M., Anagnostaki L., Landberg G., and Jirstrom K. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61 (2008) 197-203
105. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26 (2008) 3727-3734
106. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13 (2007) 1987-1994
107. Maruyama S., Fujimoto N., Asano K., and Ito A. Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. J Steroid Biochem Mol Biol 78 (2001) 177-184
108. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
109. Torrisi R., Bagnardi V., Pruneri G., Ghisini R., Bottiglieri L., Magni E., et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 97 (2007) 802-808